Erste Group Bank Brokers Decrease Earnings Estimates for BSX

Boston Scientific Corporation (NYSE:BSX) – Research analysts at Erste Group Bank lowered their FY2027 earnings estimates for shares of Boston Scientific in a report released on Tuesday, May 5th. Erste Group Bank analyst H. Engel now anticipates that the medical equipment provider will post earnings per share of $3.75 for the year, down from their previous forecast of $3.76. The consensus estimate for Boston Scientific’s current full-year earnings is $3.38 per share.

Other equities analysts have also issued research reports about the stock. TD Cowen cut their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. BTIG Research cut their target price on Boston Scientific from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Morgan Stanley decreased their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Finally, Barclays decreased their target price on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Stock Down 1.3%

NYSE:BSX opened at $55.86 on Friday. Boston Scientific has a one year low of $54.98 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.08. The company has a market cap of $83.02 billion, a PE ratio of 23.35, a P/E/G ratio of 1.03 and a beta of 0.62. The firm’s 50 day simple moving average is $65.95 and its 200 day simple moving average is $83.68.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BSX. Claret Asset Management Corp lifted its stake in shares of Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its stake in Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares during the last quarter. Kera Capital Partners Inc. increased its holdings in Boston Scientific by 3.3% during the 3rd quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 109 shares in the last quarter. Crews Bank & Trust increased its holdings in Boston Scientific by 11.6% during the 3rd quarter. Crews Bank & Trust now owns 1,061 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 110 shares in the last quarter. Finally, Outfitters Financial LLC raised its stake in shares of Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after purchasing an additional 110 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.